Telithromycin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Maxillary Sinusitis

Conditions

Maxillary Sinusitis

Trial Timeline

Dec 1, 2002 → Sep 1, 2003

NCT ID

NCT00537563

About Telithromycin

Telithromycin is a phase 3 stage product being developed by Sanofi for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00537563. Target conditions include Maxillary Sinusitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00288223	Approved	Terminated	Jan 1, 2006	Jan 1, 2007	Bronchitis, Chronic
NCT00261105	Approved	Completed	Feb 1, 2005	Dec 1, 2005	Respiratory Tract Infections
NCT00174694	Approved	Completed	Nov 1, 2004	—	Sinusitis
NCT00546676	Approved	Completed	May 1, 2004	Dec 1, 2004	Community Acquired Pneumonia (CAP)
NCT00132938	Approved	Completed	Jan 1, 2004	May 1, 2006	Chronic Bronchitis
NCT00538018	Approved	Completed	Jan 1, 2003	Jun 1, 2004	Pneumonia
NCT00273520	Phase 3	Completed	Jan 1, 2003	May 1, 2004	Asthma
NCT00537563	Phase 3	Completed	Dec 1, 2002	Sep 1, 2003	Maxillary Sinusitis
NCT00538148	Approved	Completed	Nov 1, 2002	Sep 1, 2004	Bronchitis, Chronic

Competing Products

5 competing products in Maxillary Sinusitis

See all competitors

Product	Company	Stage	Hype Score
levofloxacin	Johnson & Johnson	Phase 3	77
Azithromycin SR + Amoxiclav 1000 mg	Pfizer	Pre-clinical	22
azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin	Pfizer	Phase 3	76
Azithromycin + Telithromycin	Sanofi	Approved	84
Avelox (Moxifloxacin, BAY12-8039)	Bayer	Approved	82

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved